Reinforcement for Angelini Ventures

Hodits has been active in the European biotech scene for more than twenty years, which she has helped to shape, particularly in Germany. Prior to her appointment, she was working for Wellington Partners. As Managing Partner, she represented the company on the boards of several companies, including Minervax, Seamless, Sidekick Health, SNIPR Biome and TRiCares. She has also been instrumental in the success of several biotech companies, including Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Boston Scientific) and Themis (acquired by MSD), and was a founding investor in Bicycle Therapeutics (BCYC). Previously, she held management positions at Atlas Venture, Apax Partners and McKinsey & Company. Regina Hodits holds a PhD in biochemistry from the Vienna University of Technology and was a postdoctoral researcher at the MRC Laboratory of Molecular Biology in Cambridge, UK, under Nobel Prize winner Sir Gregory Winter.